SubEx

Pain reliever

Naproxen

The anti-inflammatory with the cleanest heart record in trials and the worst stomach record in the same ones. Whether it is safer depends which organ you mean.

Findings
5
Best evidence
★★★
Open questions
2

At a glance

Myth check

Naproxen is the heart-safe one. If you have any cardiovascular risk at all, that is the anti-inflammatory to reach for.

The randomised evidence is genuinely favourable on the heart. Pooled individual participant data from 280 placebo-controlled trials found no significant increase in major vascular events for high-dose naproxen (rate ratio 0.93), while coxibs and diclofenac rose by about a third (Coxib and traditional NSAID Trialists' Collaboration, 2013). Community observational data agree, placing naproxen lowest of the widely used drugs at 1.09 and risk-neutral at every dose studied (McGettigan and Henry, 2011). Two findings complicate it. In that same randomised pooling, naproxen carried the highest gastrointestinal risk in the set, raising serious upper gastrointestinal complications more than fourfold. And an observational analysis of everyday prescribing put naproxen's heart attack odds in the first week of use at 1.53, among the highest of the drugs examined rather than the lowest (Bally et al., 2017).

Naproxen trades a lower heart signal for a higher stomach one, so whether it is the safer choice depends entirely on which organ is being asked about.

The findingsStrongest first
1↕
Physical & bodyWhat naproxen spares your heart it costs your stomach

In pooled trials it was the only drug group with no excess of major vascular events, at 0.93, and carried the highest rate of serious upper-gut complications, 4.22.

★★★Well replicated — this finding’s sources average out to meta-analyses, systematic reviews or high-powered trials.These were high, sustained, prescription-level doses in people with arthritis, not occasional tablets. Every regimen studied raised upper-gut complications, so this is a ranking inside a class that all carried the risk, not a safe option beside a risky one. Heart failure risk was roughly doubled by every drug in the analysis, naproxen included.Click to keep this openSupport heart and blood flow
2↓
PainFor half or more of people, one tablet never halves the pain

In pooled trials after surgery, 2.5 people had to take 400 mg of ibuprofen for one more to get half their pain gone over four to six hours. Diclofenac and naproxen sat at 2.7.

★★★Well replicated — this finding’s sources average out to meta-analyses, systematic reviews or high-powered trials.Most of the underlying data come from wisdom-tooth extraction in otherwise healthy adults, a standardised research model rather than everyday pain. These are single doses measured over four to six hours and say nothing about taking something repeatedly. The overview ran no statistical test between the drugs, so these numbers sit side by side and were never compared. Some drug and dose combinations were judged unreliable because of susceptibility to publication bias.Click to keep this openRelieve pain
3↑
Physical & bodyIbuprofen sat at 1.84 and piroxicam at 7.43 for serious gut trouble

Against taking nothing, the relative risk of a serious upper-gut complication ran 1.84 on ibuprofen, 3.34 on diclofenac, 4.10 on naproxen and 7.43 on piroxicam.

★★☆Single study — solid evidence, such as one good trial or a large observational dataset, but not replicated at the top tier.These come from observational studies whose definitions of a serious complication and methods of recording who took what varied, which the authors flag themselves. The intervals are wide for the less-studied drugs, running from 1.07 to 17.81 for diflunisal. No absolute risk is supplied, and it turns heavily on age and ulcer history. Several of the drugs ranked are not in common use in most markets.Click to keep this openRelieve pain
4↕
Physical & bodyThe trial that cleared celecoxib did not dose the drugs comparably

A head-to-head trial in 24,081 arthritis patients found celecoxib no worse than ibuprofen or naproxen for heart attack and stroke. Mean daily doses ran 209 mg against 2,045 mg.

★☆☆Contested — the evidence disagrees with itself, or the finding carries a caution. A caution or conflict always shows one star, however strong the sources are.Conflicting evidenceNearly seven in ten participants stopped taking the study drug and more than a quarter stopped follow-up altogether, which blunts every comparison the trial makes. It was funded by celecoxib's manufacturer. A non-inferiority design can show one drug is not clearly worse than another; it cannot show that any of them is safe. Everyone enrolled had arthritis and raised cardiovascular risk.Click to keep this openSupport heart and blood flow
5↕
Physical & bodyNaproxen looks heart-safest in trials and riskiest in the records

Pooled randomised trials put it at 0.93 for major vascular events, the only drug group with no excess. Pooled prescribing databases put its first-week odds at 1.53.

★☆☆Contested — the evidence disagrees with itself, or the finding carries a caution. A caution or conflict always shows one star, however strong the sources are.Conflicting evidenceBoth figures are relative, and neither set of authors supplies the baseline that would turn them into a personal number. The randomised trials used high, sustained, prescription-level doses in people with arthritis. The database analysis infers what people took from prescription records, so anything bought over the counter is invisible to it. A third pooled review of community databases put naproxen lowest of all, at 1.09.Click to keep this openSupport heart and blood flow
Sources6 behind this page

Taken with something else

What the evidence says about combining Naproxen with each of these. The marker is how well established the interaction is; a caution is about the hazard, which is a different question.

What we don't know

2 open questions